LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price).

瑞士洛桑，2024年5月6日（环球通讯社）--ADC Therapeutics SA（纽约证券交易所：ADCT）今天宣布，它已同意以包销发行的方式出售其13411912股普通股，价格为每股4.900美元，并向某些选择代替普通股的投资者出售预售认股权证，以购买8163265股普通股，价格为每股预售认股权证4.812美元（即发行中普通股的发行价格减去行权价格）。

The gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the Company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105.0 million. The offering is expected to close on May 8, 2024, subject to customary closing conditions..

在扣除公司应付的承销折扣和发行费用以及假设不行使预先出资的认股权证之前，发行的总收益预计约为1.05亿美元。根据惯例的交割条件，此次发售预计于2024年5月8日结束。。

Jefferies, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.

杰弗里斯（Jefferies）、古根海姆证券（Guggenheim Securities）和康托（Cantor）担任此次发行的联合账簿管理人。

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on March 14, 2024. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov.

与这些证券相关的登记声明已提交给美国证券交易委员会（“SEC”），并于2024年3月14日宣布生效。与本次发行相关的初步招股说明书补充资料已提交给SEC，可在SEC网站www.SEC.gov上查阅。

A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained for free from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 821-7388, email: ProspectusDepartment@Jefferies.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com..

与本次发行相关的最终补充招股说明书和随附招股说明书将提交给美国证券交易委员会，并可在美国证券交易委员会网站www.SEC.gov上查阅。与本次发行相关的最终补充招股说明书和随附招股说明书的副本（如有）可从Jefferies LLC免费获得，收件人：纽约州麦迪逊大道520号股权辛迪加招股说明书部，电话：（877）821-7388，电子邮件：ProspectusDepartment@Jefferies.com；古根海姆证券有限责任公司，收件人：股票辛迪加部，330 Madison Avenue，8th Floor，New York，New York 10017，或致电（212）518-9544，或发送电子邮件至GSEquityProspectusDelivery@guggenheimpartners.com；或Cantor Fitzgerald&Co.，收件人：Capital Markets，110 East 59th Street，6th Floor，New York，New York 10022，或发送电子邮件至prospectus@cantor.com..

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何州或司法管辖区的证券法登记或取得资格之前，在任何州或司法管辖区出售这些证券都是非法的。

There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of ADC Therapeutics SA, such as the common shares, in or into Switzerland within the meaning of the Swiss Financial Services Act ('FinSA') and these securities will not be listed or admitted to trading on the SIX Swiss Exchange or on any other regulated trading venue (exchange or multilateral trading facility) in Switzerland.

根据《瑞士金融服务法》（“FinSA”）的规定，不打算或不允许直接或间接在瑞士或在瑞士境内公开发售、招揽、出售或宣传ADC Therapeutics SA的任何证券，例如普通股，并且这些证券不会在瑞士的六家瑞士交易所或任何其他受监管的交易场所（交易所或多边交易机构）上市或交易。

Neither this document nor any other offering or marketing material relating to these securities, such as the common shares, constitutes or will constitute a prospectus pursuant to the FinSA, and neither this document nor any other offering or marketing material relating to the common shares constitutes a prospectus pursuant to the FinSA, and neither this document nor any other offering or marketing material relating to the common shares may be publicly distributed or otherwise made publicly available in Switzerland..

本文件或与这些证券有关的任何其他发售或营销材料（如普通股）均不构成或将构成《金融情报法》规定的招股说明书，本文件或与普通股有关的任何其他发售或营销材料均不构成《金融情报法》规定的招股说明书，本文件或与普通股有关的任何其他发售或营销材料均不得在瑞士公开发行或以其他方式公开提供。。

About ADC Therapeutics

关于ADC治疗

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors..

ADC Therapeutics（纽约证券交易所：ADCT）是一家商业阶段的生物技术公司，通过其下一代靶向抗体-药物偶联物（ADC）帮助改善癌症患者的生活。该公司正在推进其专有的ADC技术，以改变血液系统恶性肿瘤和实体瘤患者的治疗模式。。

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

ADC Therapeutics的CD19定向ADC ZYNLONTA（loncastuximab tesirine lpyl）获得了FDA的加速批准，并获得了欧盟委员会的条件性批准，用于治疗两种或多种全身治疗后复发或难治性弥漫性大B细胞淋巴瘤。ZYNLONTA也正在与其他药物和早期治疗方案联合开发。

In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development..

除ZYNLONTA外，ADC Therapeutics在正在进行的临床和临床前开发中还拥有多个ADC。。

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey.

ADC Therapeutics总部位于瑞士洛桑（Biopôle），并在伦敦和新泽西州开展业务。

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

ZYNLONTA®是ADC Therapeutics SA的注册商标。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the underwritten offering. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear”, or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words.

本新闻稿包含1995年《私人证券诉讼改革法案》安全港条款所指的前瞻性陈述，包括有关承销发行的陈述。在某些情况下，您可以通过“可能”、“将”、“应该”、“将”、“预期”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“潜在”、“似乎”、“寻求”、“未来”、“继续”或“出现”等术语或类似表达来识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词。

Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described, including those contained in the “Risk Factors” section of the Company's Annual Report on Form 10-K and in the Company's other periodic reports and filings with the Securities and Exchange Commission.

前瞻性陈述受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与所描述的结果存在重大差异，包括公司年度报告表10-K中“风险因素”部分以及公司其他定期报告和提交给证券交易委员会的文件中所包含的风险和不确定性。

These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements.

这些声明涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果、业绩、成就或前景与此类前瞻性声明中表达或暗示的任何未来结果、业绩、成就或前景存在重大差异。

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law..

公司提醒投资者不要过度依赖本文件中的前瞻性声明。除法律要求外，公司没有义务修改或更新这些前瞻性声明，以反映本新闻稿发布日期后的事件或情况。。

CONTACT:

联系人：

Investors and Media

投资者和媒体

Nicole Riley

赖莉

ADC Therapeutics

ADC治疗学

Nicole.Riley@adctherapeutics.com

Nicole.Riley@adctherapeutics.com

+1 862-926-9040

+1 862-926-9040